Cite
HARVARD Citation
Appenzeller, S. et al. (2019). The identification of patient‐specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild‐type melanomas. Cancer. 125 (4), pp. 586-600. [Online].